Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cancer Genetics Expands BioDiscovery's Nexus Copy Number Platform

Published: Thursday, April 03, 2014
Last Updated: Thursday, April 03, 2014
Bookmark and Share
Expansion to identify novel biomarkers predictive of cancer outcomes.

Cancer Genetics, Inc. and BioDiscovery, Inc. have announced expansion of the Nexus Copy Number Discovery platform in CGI research to uncover novel biomarkers which are predictive of cancer outcomes.

“Cancer Genetics has been able to leverage the Nexus Copy Number platform’s unique ability to quickly digest large data sets to uncover correlations between genomic events and clinical factors in their discovery efforts,” says Louis J. Culot, Vice President of Business Development and Marketing at BioDiscovery. “Cancer Genetics is an emerging leader in DNA cancer diagnostics. We are excited about the opportunity to play a role in the work being done and the impact that work is having on improving patient outcomes.”

“The Nexus Copy Number product is one of the primary analytic and collaboration tools for CGI’s R&D platform” says Jane Houldsworth, PhD, Vice President of Research and Development at CGI, “allowing our scientists to quickly mine complex data sets for underlying diagnostic and prognostic markers.”

CGI expects to utilize the many new features in Nexus Copy Number version 7.5, such as the ability to automatically classify samples with particular genomic aberrations, and plans to take advantage of the NGS support in the updated version.

According to CGI, the team at BioDiscovery has been highly responsive to scientists’ needs, accelerating research and development.

BioDiscovery Nexus Copy Number software offers simple yet powerful tools for copy number and sequence variation (CNV) analysis and visualization from microarrays and next generation sequencing (NGS), for analysis of complex data such as solid tumor samples and complex constitutional disease.

The scientist-driven software embeds powerful statistical tools designed specifically for the end-user, allowing rapid detection of chromosomal aberrations and identification of affected pathways.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioDiscovery Awarded National Institutes of Health SBIR Grant
SBIR Phase I grant to improve the copy number variation data from TCGA.
Thursday, July 10, 2014
N-of-One and BioDiscovery Partner
Partnership equips laboratories and oncologists with a foundation for genomic data analysis through to therapeutic options.
Tuesday, March 25, 2014
Cancer Centers Renew and Expand BioDiscovery’s Nexus Copy Number Software Licenses
BioDiscovery announces a number of license renewals and expansions of its Nexus Copy Number product at leading cancer research centers.
Wednesday, December 16, 2009
Fox Chase Cancer Center Adopts Nexus Copy Number and Nexus Expression
The center's Keystone Program in Blood Cell Development and Cancer gains a site license for two bioinformatics software programs from BioDiscovery.
Wednesday, February 11, 2009
Scientific News
Making Metabolite Identification More Efficient
Metasense combines the industry's most-comprehensive metabolic transformation prediction with efficient analysis of LC/MS analytical measurements to identify, visualize, and report chemical biotransformations.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Applying Deep Learning to Drug Discovery
Researchers train deep neural networks to predict the therapeutic use of large number of multiple drugs using gene expression data obtained from high-throughput experiments on human cell lines.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
Making Genetic Data Easier to Search
Scripps team streamlines biomedical research by making genetic data easier to search.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!